Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia Article

Williams, R, Kopala, L, Malla, A et al. (2006). Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia . Acta Psychiatrica Scandinavica, 113(SUPPL. 430), 12-21. 10.1111/j.1600-0447.2006.00757.x

cited authors

  • Williams, R; Kopala, L; Malla, A; Smith, G; Love, L; Balshaw, R

abstract

  • Objective: To evaluate over a 2-year period, patients from academic/non-academic centres, from each region of Canada, to determine whether location or other variables such as medication type, gender or income was associated with outcome as defined by non-hospitalization and persistence on original treatment. Method: A total of 448 patients were recruited from academic and non-academic centres across all provinces of Canada and followed up for 2 years. Results: Patients from British Columbia had significantly lower rates of hospitalization than patients from other provinces. Male patients showed greater symptomatic improvement at 2 years from initial assessment compared to females. Patients on clozapine, risperidone and olanzapine were least likely to be hospitalized. Conclusion: There were some regional differences noted in both utilization of types of antipsychotic medications and hospitalization rates. In this sample of stable out-patients over 70% who started on monotherapy with clozapine, risperidone, olanzapine and quetiapine remained on the same medication over the 2-year study period. Copyright © Blackwell Munksgaard 2006.

authors

publication date

  • January 1, 2006

published in

Digital Object Identifier (DOI)

start page

  • 12

end page

  • 21

volume

  • 113

issue

  • SUPPL. 430